Table 1

Clinical information and analysis results

Demographics

Clinical Characteristics

Immunohistochemical Analysis²

Patient

Age

Sex

Stage

Tumor size (cm)¹

CD68

CD163

p value

1

21

F

IIA

6

2

1

0.01

2

73

M

IIIB

3

2

1

3

37

M

IIA

2

3

2

4

59

F

IIA

4.3

3

3

5

42

F

IIA

4

3

3

6

94

M

IIA

2.2

3

1

7

20

F

IIIA

> 10

2

1

8

19

F

IIA

> 10

3

3

9

51

M

IVA

> 10

3

3

10

28

M

IIA

2.5

2

1

11

33

F

IVB

3

2

2

12

62

F

IIB

2

2

2

13

15

F

IIIA

> 10

2

2

14

22

M

IIA

2

1

1

15

23

F

IIB

> 10

1

1

16

33

M

IA

2.8

2

2

17

48

M

IB

3

2

2

18

17

F

IVB

5

2

2

19

25

F

IIB

17

1

1

20

52

M

IVB

4

3

3

21

45

M

IVB

11

2

1

22

20

M

IIB

2

3

3

23

64

M

IVB

5.5

1

1

24

23

M

IIA

4

3

3

25

14

M

IVB

9.4

2

2

26

14

F

IVB

3

1

1

27

35

M

IIA

1.8

2

1

28

54

M

IIIB

4.9

2

1

29

40

M

IV

2.2

3

1

30

21

F

IA

10

3

3

31

34

F

IA

6.3

2

2

32

17

F

IVB

5.1

2

3

33

22

F

IIB

7.5

2

2

34

66

F

IIIA

1.7

2

2

35

26

F

IVA

1.6

1

1

36

24

M

IV

6.3

2

2

37

35

M

IIA

1.5

3

3

38

23

F

IIA

2.5

3

3

39

26

M

IVB

2.3

2

2

40

18

F

IIIA

6

1

2

41

49

M

IA

9

2

2

42

70

F

IVB

2.4

2

1

43

21

M

IIA

3

1

1

44

38

M

IA

4

3

3

¹ The tumor size was calculated as the largest diameter of the largest involved LN

² Score of 1 = 0-5%, 2 = 5-25%, and 3 = > 25% staining of total cells in HRS rich areas

Harris et al. Diagnostic Pathology 2012 7:12   doi:10.1186/1746-1596-7-12